However, these studies were performed using specimens from patients with diverse breast cancer histological sub-types and ER/PR/HER2 receptor status [44], while our work focused on a subgroup of ER-positive, HER2 negative breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.